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Chronic Adolescent Exposure to Delta-9-Tetrahydrocannabinol
in COMT Mutant Mice: Impact on Indices of Dopaminergic,
Endocannabinoid and GABAergic Pathways
A´ine T Behan*,1, Magdalena Hryniewiecka1, Colm MP O’Tuathaigh2,6, Anthony Kinsella2, Mary Cannon1,
Maria Karayiorgou3, Joseph A Gogos4,5, John L Waddington2 and David R Cotter1
1Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; 2Molecular and Cellular Therapeutics, Royal College of Surgeons
in Ireland, Dublin, Ireland; 3Department of Psychiatry and Genetics & Development, Columbia University, NY, USA; 4Department of Physiology
and Cellular Biophysics, Columbia University, NY, USA; 5Department of Neuroscience, Columbia University, NY, USA
Q1
Cannabis use confers a two-fold increase in risk for psychosis, with adolescent use conferring an even greater risk. A high-low activity
polymorphism in catechol-O-methyltransferase (COMT), a gene encoding the COMT enzyme involved in dopamine clearance in the
brain, may interact with adolescent cannabis exposure to increase risk for schizophrenia. The impact of such an interaction on central
neurotransmitter pathways implicated in schizophrenia is unknown. Male mice with knockout of the COMT gene were treated
chronically with delta-9-tetrahydrocannabinol (THC) during adolescence (postnatal day 32–52). We measured the size and density of
GABAergic cells and the protein expression of cannabinoid receptor 1 (CB1R) in the prefrontal cortex (PFC) and hippocampus (HPC) in
knockout mice relative to heterozygous mutants and wild-type controls. Size and density of dopaminergic neurons was also assessed in
the ventral tegmental area (VTA) across the genotypes. COMT genotypeTHC treatment interactions were observed for:
(1) dopaminergic cell size in the VTA, (2) CB1R protein expression in the HPC, and (3) parvalbumin (PV) cell size in the PFC. No effects
of adolescent THC treatment were observed for PV and dopaminergic cell density across the COMT genotypes. COMT genotype
modulates the effects of chronic THC administration during adolescence on indices of neurotransmitter function in the brain. These
findings illuminate how COMT deletion and adolescent cannabis use can interact to modulate the function of neurotransmitters systems
implicated in schizophrenia.
Neuropsychopharmacology (2012) 0, 000–000. doi:10.1038/npp.2012.24
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INTRODUCTION
The traditional hypothesis, widely held for several decades,
is that increased dopaminergic function underlies the
pathology of schizophrenia (Carlsson, 1978). More recently,
the dopamine hypothesis of schizophrenia has been revised,
with excess mesolimbic dopamine being secondary to lower
dopamine levels in the prefrontal cortex (PFC) (Davis et al,
1991). In this context, the catechol-O-methyltransferase
(COMT) gene on chromosome 22q11, a region implicated in
schizophrenia, is functionally significant. It encodes the
COMT enzyme responsible for the degradation of dopa-
mine, particularly in the PFC. Furthermore, a valine to
methionine substitution (valine substitution for methionine
at the 158/108 locus Val158Met) within COMT was shown
to reduce enzymatic activity of COMT, and thus lead to a
slower breakdown of dopamine (Chen et al, 2004; Lachman
et al, 1996). Reports have shown that a functional poly-
morphism in the COMT gene can moderate the association
between cannabis use and psychosis (Caspi et al, 2005;
Harrison and Weinberger, 2005; Tunbridge et al, 2006; van
Os et al, 2010), but not all studies support such associations
(Zammit et al, 2011). One particular study (Caspi et al,
2005) demonstrated that psychosis was most likely in those
who used cannabis during adolescence and were homozygous
for the COMT Val allele with the Met allele generating a
four-fold reduction in enzymatic activity.
Mutant mice with deletion of the COMT gene have further
elucidated the role of COMT in terms of dopamine-related
function (Babovic et al, 2007; Seamans and Yang, 2004) of
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PFC-mediated cognition (Babovic et al, 2007; Gogos et al,
1998) and of spatial working memory. Thus, they have
proved valuable in demonstrating the complexities of the
inverted U-shaped dose–response relationship between
PFC-mediated function and cortical dopaminergic activity
involving the COMT gene, whereby a narrow range of
dopamine can benefit PFC function and either insufficient
or excessive dopamine can impair cognitive function
(Castner et al, 2000; Goldman-Rakic et al, 2000; Seamans
and Yang, 2004; Tunbridge et al, 2006). MoreoverQ2 , a com-
panion study by the authors have shown that the effects of
chronic adolescent exposure to delta-9-tetrahydrocannabi-
nol (THC) on behaviors related to psychosis and memory
are modified in COMT mutant mice (O’Tuathaigh et al,
2010). No complementary analysis on neuronal structure
has been performed in COMT mutant mice. Although it is
known that single polymorphisms involve smaller effects on
enzyme activity in humans, the COMT mutant mice provide
an adequate model to further explore the modulatory role of
COMT, following adolescent cannabis use.
Cannabis use alone is not necessary or sufficient to cause
the development of schizophrenia, which suggests that the
association may be because of a genetic vulnerability to the
effects of cannabis. In support of this, patients with schizo-
phrenia or with an established vulnerability to psychosis are
much more sensitive to the effects of cannabis than control
subjects (D’Souza et al, 2005; Henquet et al, 2005; Stefanis
et al, 2004; van Os et al, 2002; Verdoux et al, 2003).
Nonetheless, consumption of cannabis is a risk factor for
developing schizophrenia (Arseneault et al, 2004; Henquet
et al, 2005; Moore et al, 2007), and the risk of developing
psychotic symptoms is highest when cannabis is consumed
during adolescence (Arseneault et al, 2002; Caspi et al, 2005;
Konings et al, 2008; McGrath et al, 2010; Moore et al, 2007),
possibly because the brain is still developing (Ehrenreich
et al, 1999; Pistis et al, 2004; Pope et al, 2003; Schneider and
Koch, 2003). Cannabinoid receptors mature slowly, reach-
ing maximal levels during adolescence that possibly reduce
later in life due to post-adolescent pruning, in a similar
manner to that described for dopamine receptors (Belue
et al, 1995; McLaughlin et al, 1994; Seeman, 1999). Studies
have shown that heavy cannabis use, especially during
adolescence, could contribute to additional changes in
global brain structures (Arnone et al, 2008; Matochik et al,
2005; Welch et al, 2010; Wilson and Cadet, 2009; Yucel et al,
2008). However, the effect of cannabis use during adoles-
cence on specific cell populations and their structure,
particularly those implicated in schizophrenia, is less well
understood.
THC, the main psychoactive ingredient of cannabis, is
known to mediate its effect by binding to the cannabinoid
receptor 1 (CB1R) (Pertwee, 2005); this is the main canna-
binoid receptor in the brain, being expressed predomi-
nantly in the hippocampus (HPC), PFC, cerebellum, and
basal ganglia (Freund et al, 2003). Endocannabinoids, the
endogenous ligands of CB1R, are released by post-synaptic
neurons to activate CB1R on neighboring presynaptic
neurons, which can in turn inhibit presynaptic neurotrans-
mitter release of g-aminobutyric acid (GABA) and glutamate,
as well as modulating the dopamine system (Chevaleyre
et al, 2006). It is also thought that dopaminergic midbrain
neurons are modulated by endocannabinoid cortical
neurons (Chevaleyre et al, 2006). Thus, the major neuronal
populations modulated by cannabinoids are also ones
implicated in schizophrenia (Laviolette and Grace, 2006;
Lisman et al, 2008). How adolescent cannabis use and
COMT genotype interact to modulate such structural changes,
particularly in neuronal populations implicated in schizo-
phrenia, is not yet understood.
Examination of morphological parameters such as neuronal
cell size, cell density, and protein expression can provide
complementary information on a neurons capacity to func-
tion (Behan et al, 2009; Cotter et al, 2002a, b). Recent
reports have demonstrated deficits in GABAergic neuronal
size and density (Cotter et al, 2002a) to be an indicator of
pathophysiological deficits in schizophrenia and to be in line
with functional assessments of the same neuronal popula-
tions (Hashimoto et al, 2003; Volk et al, 2001). In this study,
we aimed to elucidate the impact of chronic THC treatment
during adolescence on morphological indices of dopami-
nergic, cannabinoid, and GABAergic function in the brain
and how they might be modified in COMT mutant mice.
MATERIALS AND METHODS
Animals
Mice containing the mutated COMT allele were generated at
Rockefeller University, New York, NY, USA, and back-
crossed to C57BL6 mice for 10 generations (Gogos et al,
1998); breeding and genotyping at the Royal College of
Surgeons in Ireland were as described previously (Babovic
et al, 2007). After weaning on postnatal day (PND) 21, pups
from litters of the same generation were housed in groups of
three to five per cage and maintained at 21±11C on a 12-h
light/dark cycle (07:00 hours on; 19:00 hours off), with ad
libitum access to food and water. Males of wild type (WT),
COMT heterozygous (HET) and COMT knockout (KO)
genotypes, 6–7 mice per treatment and genotype, were
treated with THC 8.0mg/kg subcutaneously or vehicle over
20 consecutive days (McKinney et al, 2008) from PND
32–52, a period corresponding to adolescence in mice
(Vazdarjanova et al, 2011) . These studies were approved by
the Research Ethics Committee of the Royal College of
Surgeons in Ireland. They were conducted under license
from the Department of Health and Children, in accordance
with Irish legislation and the European Communities
Council Directive 86/609/EEC for the care and use of
experimental animals, and from the Environmental Protec-
tion Agency in relation to the contained use of genetically
modified organisms. All efforts were made to minimize the
number of animals used and their suffering.
Drugs
Delta-9-tetrahydrocannabinol (Sigma Aldrich, St Louis,
MO, USA) was dissolved in saline: cremaphor: ethanol
(18 : 1 : 1); vehicle controls received identical injections of
the final saline: cremaphor: ethanol solution.
Immunofluorescent Staining
Animals were killed at PND 150–160 by cervical dislocation.
Whole brains were removed and post-fixed in 4%
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paraformaldehyde (24 h), cryoprotected in daily steps of
24 h in 10, 20, and 30% sucrose solution, and frozen in
isopentane cooled on dry ice.
Serial coronal sections (20 mm) were collected at the PFC,
Bregma 1.542.34mm, the HPC, Bregma 1.34 to
3.52mm, and the ventral tegmental area (VTA, Bregma
3.08 to 3.88mm). Briefly, sections were incubated with
primary antibodies against (1) monoclonal tyrosine hydro-
xylase (TH), a marker of dopaminergic neurons (1 : 500,
Millipore, Cork Ireland) (2) monoclonal cannabinoid 1
receptor (CB1R, 1 : 2000, a kind gift from Dr Maurice
Elphick), and (3) polyclonal parvalbumin (PV), a marker of
a subset of GABAergic neurons (1 : 1000, Abcam, Cam-
bridge, UK), diluted in 5% NGS/1 PBS-T. PV and TH
antibodies were revealed by fluorescence using the respec-
tive conjugated Alexa Fluor 488 secondary antibody
(1 : 2000 in 5% NGS/PBS-T) and cover slipped using DAKO
fluorescent mounting medium. CB1R antibody was visua-
lized using the tyramide signal amplification kit (Perkin
Elmer, Dublin, Ireland). All sections from each experi-
mental group were immunostained in one single run under
identical conditions with each run. A negative control,
containing adjacent sections incubated in secondary anti-
body alone, that is, with the omission of the respective
primary antibody, was included in every run. All morpho-
metric measures were made by an observer blind to
genotype and treatment.
Quantitative Analysis of CB1R, PV, and TH
Immunoreactivity
All analyses were carried out on a Leica DM2500 micro-
scope (Leica Microsystems, Ireland), a cooled monochrome
12-bit camera QI-IMAGING CAMERA Fast 1394 (Media
Cybernetics, UK) and a Prior  100 x, y-motorized stage
and stage controller (Media Cybernetics, UK) attached to a
Heidenhain z axis depth gauge (Heidenhain, Germany).
Cross-sectional areas of VTA, PFC, and HPC were captured
at  20 magnification and tiled using standardized exposure
conditions. Boundaries of the VTA were defined by exa-
mining the size and shape of TH-IR neuronal groups and
juxtaposition of other landmarks through reference to
adjacent Nissl-stained VTA sections and a standard mouse
atlas (Paxinos, 2008). The VTA was distinguished by the TH
immunoreactive region bordered medially by the inter-
peduncular nucleus (IPN), laterally and ventrally by the
substantia nigra pars compacta (SNpc) and medial lemnis-
cus (ML), and dorsally by the parabrachial pigmented
nucleus. Representative TH-immunoreactive sections of the
VTA at 3.00mm, 3.30mm, and 3.60mm with respect
to Bregma are shown in Figure 1a. The location of PFC
and HPC was defined using standard cytoarchitecture and
subcortical landmarks as delineated in the Paxinos and
Watson mouse brain atlas (Paxinos, 2008). Additionally,
adjacent sections were stained with cresyl violet as described
previously (Behan et al, 2010) and superimposed onto
immunofluorescent images to accurately delineate PFC as
well as the hippocampal formation, which included CA1,
CA2/3, CA4, dentate gyrus, and subiculum.
Density and cell somal size of PV+ neurons (Figure 1b)
and TH+ immunoreactive neurons (Figure 1d) were deter-
mined using morphometric methods, as outlined previously
(Cotter et al, 2002a). Areal fluorescent intensity of CB1R
staining was also measured (Figure 1c). Density (cells/mm2),
two-dimensional cell somal size (mm2), and fluorescent
intensity (mean fluorescent intensity/mm2) were measured
using Stereology-Pro 2.5 image analysis software (Kinetic
Imaging, Liverpool, UK). From each animal, four cross-
sectional areas of the PFC, six cross-sectional areas of the
HPC, and four cross-sectional areas of the VTA were analyzed
for the respective PV+ , CB1R+ , and TH+ morphometric
assessments (Figures 1b–d). The volume of the entire VTA
(Figure 1a) was also estimated using stereological tools by
the Cavalieri principle and the point-counting method
(Behan et al, 2010; Gundersen et al, 1988). The coefficient of
error for all morphometric measurements was o5%.
Statistical Analysis
All morphological measurements were analyzed using analysis
of variance (ANOVA) with post-hoc comparisons by Fisher’s
test and corrected for multiple comparisons using Bonfer-
roni correction as outlined previously (Babovic et al, 2007;
O’Tuathaigh et al, 2007). For these measurements, we
hypothesized a priori that the effects of chronic THC
treatment during adolescence on dopaminergic, cannabi-
noid, and GABAergic neuronal populations in PFC, HPC,
and VTA, respectively, were modified by COMT genotype.
All statistical analyses were carried out using the SPSS
software package (Version 14, SPSS, Chicago, IL, USA).
RESULTS
See Table 1 for a summary of morphological and densito-
metric assessments carried out for this study.
TH Cell Counts in VTA
A genotypeTHC treatment interaction for TH+ neuronal
cell somal size in VTA (F2,25¼ 8.12; p¼ 0.002) reflected an
action of THC to reduce TH+ neuronal cell somal size in
COMT KO (94.43±7.86 mm2) but not in WT (111.20±
12.90mm2), or COMT HET (112.26±14.46 mm2) (Figure 2a).
An effect of THC treatment on TH+ cell density was
observed in VTA (F1,25¼ 10.44; p¼ 0.003), whereby THC
reduced TH+ cell density in a manner that did not differ
between the genotypes (Figure 2b).
No effect of THC treatment on VTA volume was observed
(Figure 2c).
CB1R Intensity in the PFC and HPC
An effect of genotype on CB1R intensity was observed in the
PFC (F5,25¼ 8.07; p¼ 0.01), whereby COMT HET mice
(63.54±5.90 intensity/mm2) and COMT KO mice (64.85±
1.39 intensity/mm2) expressed a higher CB1R intensity than
WT (60.17±5.14 intensity/mm2) (Figure 3a). Conversely, an
effect of genotype on CB1R intensity was observed in HPC
(F5,25¼ 4.75; p¼ 0.015) whereby COMT KO mice (33.76±
3.10 intensity/mm2) expressed a lower CB1R intensity than
WT (37.27±3.30 intensity/mm2) (Figure 3b). No effects of
THC on CB1R intensity were observed in PFC or HPC.
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PV Cell Somal Size and Density in PFC and HPC
An effect of genotype on PV cell size was observed in the
PFC (F2, 25¼ 6.36; p¼ 0.006), whereby PV cells were smaller
in COMT HET (140.67±12.07mm2) than in COMT KO
(169.32±11.66mm2), or WT (146.42±7.89mm2) (Figure 3c).
A genotypeTHC treatment interaction for PV cell somal
size in PFC (F2, 25¼ 7.04; p¼ 0.004) reflected an action of
THC to increase PV cell somal size in WT, to be without
effect in HET and to decrease PV cell somal size in COMT
KO (Figure 3c). An effect of genotype on PV cell size was
observed in HPC (F2, 25¼ 8.021; p¼ 0.002), whereby PV
cells were smaller in COMT KO (165.44±3.58 mm2) and
particularly in COMT HET (154.83±11.91 mm2) than in WT
(171.85±8.01 mm2) (Figure 3d). There were no effects of
genotype, THC treatment or geneTHC treatment inter-
actions for PV cell density in PFC or HPC (Figures 3e and f).
NPG_NPP_NPP201224
Figure 1 Delineation of ventral tegmental area (VTA) and representative immunofluorescent staining of PV, cannabinoid receptor 1 (CB1R), and TH in
mouse brain. (a) Delineation of VTA using TH immunofluorescence at Bregma level 3.0mm, 3.3mm, and 3.6mm. VTA boundary landmarks are the
interpeduncular nucleus (IPN) at the ventromedial border, the medial lemnicsus (ML), and the substantia nigra pars compacta (SNpc) at its most lateral and
ventrolateral border; scale bar, 200 m. (b) PV immunoreactivity in prefrontal cortex (PFC) (left), hippocampus (HPC) (centre), and negative control (NEG) in
HPC (right); scale bar, 200 m. (c) CB1R staining in PFC (left), HPC (centre), and CB1R-negative control in PFC (right); scale bar, 200 m. (d) TH
immunoreactivity in VTA (left, and inset showing TH-positive cell soma of neuron) and TH-negative control in VTA (right); scale bar, 100 m.
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It was noteworthy that CB1R intensity inversely corre-
lated strongly with PV cell size in PFC (r¼0.55, po0.001)
and HPC (r¼0.46, po0.01).
DISCUSSION
In this study, the effects on morphological indices of
GABAergic, dopaminergic, and cannabinoid function were
assessed in COMT mutant mice, following chronic THC
treatment during adolescence. To our knowledge, this is the
first study to assess the combined effects of COMT activity
and adolescent THC administration on cannabinoid-modu-
lated neuronal populations implicated in schizophrenia. As
human polymorphisms elicit smaller effects on enzyme
activity, our COMT mutant mice do not serve to replicate
such findings here but to illuminate the modulatory role of
COMT on other neuronal populations in the brain, following
chronic THC administration. On the basis of previous
findings, indicating a sexually dimorphic effect of COMT
function on psychiatric phenotypes to be evident primarily
in males (Gogos et al, 1998; O’Tuathaigh et al, 2010), we
assessed male COMT mutant mice. On the basis of our
behavioral studies on COMT mutant mice, indicating COMT
genotype to influence the effects of adolescent THC admini-
stration on schizophrenia-related behavioral phenotypes
(O’Tuathaigh et al, 2010), the same treatment regimen was
employed in the present study. We examined morphological
parameters such as neuronal cell size, cell density, and
protein expression to obtain morphological correlates on
the functional capacity of specific neuronal populations
(Behan et al, 2009; Cotter et al, 2002a, b). Given that the
COMT mutant model was based on a higher COMT activity
being a risk factor for schizophrenia, our results show that
COMT deletion is associated with: (1) release of an effect of
adolescent THC treatment in VTA that reduced dopami-
nergic cell size, (2) increased CBR1 intensity in PFC, reduced
CBR1 intensity in HPC, and a shift in effect of adolescent
THC treatment in HPC and PFC from reduction to increase
in CBR1 intensity, and (3) increased GABAergic cell size in
PFC and HPC, and a shift in effect of adolescent THC treatment
in PFC and HPC from increase to decrease in GABAergic
cell size. Adolescent THC treatment also reduced dopami-
nergic cell density. COMT KO mice demonstrated the pro-
minent structural neuronal deficits in this study.
COMT Modulation of Adolescent THC Effects on
Neurotransmitter Systems
Dopaminergic neurons. A functional polymorphism in the
COMT gene moderates the risk to develop psychosis,
following adolescent cannabis use with individuals homo-
zygous for the COMT Val allele possessing a higher risk for
psychosis, following adolescent cannabis use (Caspi et al,
2005; Henquet et al, 2006). This is attributable to increased
COMT activity associated with the COMT Val allele in the
PFC leading to a reduction in PFC dopamine neurotrans-
mission and increased mesolimbic dopamine signaling; the
converse would be hypothesized for the COMT Met allele
(Akil et al, 2003; Bilder et al, 2004). THC challenge studies
in humans have demonstrated significant increases in
striatal dopamine release after acute administration of
NPG_NPP_NPP201224
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inhaled THC (Bossong et al, 2009); however, such findings
could not be replicated in a larger cohort (Stokes et al, 2010,
2011). In animal studies, THC increased dopaminergic
neuronal firing and dopamine release in the striatum and
PFC (Cheer et al, 2004; Chen et al, 1990; French, 1997;
French et al, 1997; Pistis et al, 2002; Tanda et al, 1997). PFC
is the dominant COMT site in the brain for modulating
dopamine metabolism whereas the dopamine transporter
(DAT), found at a much higher density in the striatum, is
mainly responsible for regulating striatal dopamine levels
(Scatton et al, 1985; Yavich et al, 2007) . Male COMT KO
mice used in this study have previously demonstrated
higher basal levels of dopamine release, dopamine levels,
and its metabolites in PFC of COMT KO mice (Gogos et al,
1998; O’Tuathaigh et al, 2011). Given the evidence of
COMTs regulatory role in the PFC (and not the striatum)
(Scatton et al, 1985; Yavich et al, 2007), we would speculate
that changes to COMT activity in PFC are having a knock-
on effect on the activity and output of dopaminergic cortical
neurons. It is possible that our observations of smaller
tyrosine hydroxylase-labeled dopaminergic neurons in VTA
in COMT KO mice following THC treatment occurs in
response to altered input from cortical dopaminergic neurons
(Akil et al, 2003). This further highlights a role for
prefrontal COMT levels in the regulation of and commu-
nication between cortical and subcortical dopaminergic
neuronal populations.
The aforementioned pattern of midbrain dopaminergic
signaling is similar to that proposed to be present among
subjects carrying the COMT Met allele (Akil et al, 2003;
Bilder et al, 2004). We propose that lower cortical COMT
activity may lead, through increased cortical dopaminergic
activity, to reduced midbrain dopaminergic function, and
hence, neuronal size. No changes in the structure of VTA
dopaminergic neurons were observed in male COMT WT
and HET mice. Our findings indicate that COMT genotype
and adolescent THC exposure together can modulate
dopaminergic neuronal structure in the mesolimbic system.
Changes in dopaminergic neuron structure may reflect a
cellular pathology that accompanies changes in dopami-
nergic activity as have been observed in other neuronal
populations implicated in schizophrenia (Cotter et al, 2002a).
Relating such structure–function findings are relevant to
our understanding of the pathophysiology of schizophrenia,
as excessive activity of dopaminergic neurons in VTA has
also been proposed to have a role in the emergence of
psychotic symptoms in schizophrenia (D’Souza et al, 2005;
Henquet et al, 2005; Stefanis et al, 2004; van Os et al, 2002;
Verdoux et al, 2003).
Cannabinoid 1 receptor and the endocannabinoid path-
way. Dysfunction in PFC is strongly implicated in schizo-
phrenia (Lafourcade et al, 2007) and within it, CB1R
expression is reported to be reduced (Eggan et al, 2010).
Our observation of reduction in CB1R expression in PFC
and HPC of WT mice following adolescent THC treatment is
in accordance with previous CB1R binding and protein
expression studies in animals, following THC treatment
(Romero et al, 1997, 1998). Furthermore, this finding is in
line with what we would have predicted from our model
based on a higher COMT activity and THC administration
being a risk factor for schizophrenia (Caspi et al, 2005).
Conversely, we observed a shift in this pattern, from
reduction to increase in CB1R expression in PFC and HPC,
in COMT KO mice following adolescent THC treatment.
This affirms structural significance and interdependence of
NPG_NPP_NPP201224
Figure 2 Somal size (a), cell density (b), and ventral tegmental area
(VTA) volume (c) for TH-positive cells in VTA during adulthood, following
adolescent treatment with 8.0mg/kg delta-9-tetrahydrocannabinol (THC)
or vehicle (0). Data are means±SEM; *po0.015.
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COMT activity and the endocannabinoid system (Cheva-
leyre et al, 2006; Fride, 2005), and may be relevant to the
known association of cannabis use with increased levels of
psychotic symptoms (D’Souza et al, 2005; Henquet et al,
2005; Stefanis et al, 2004; van Os et al, 2002; Verdoux et al,
2003). It also emphasizes further the developmental period
of adolescence and its vulnerability to subsequent effects of
cannabis.
THC is known to affect endocannabinoid neurotransmis-
sion with components of this endocannabinoid pathway shown
to be involved in regulating dopaminergic neurotransmission,
particularly in the striatum (Cheer et al, 2004; Chen et al,
1990; Tanda et al, 1997). Furthermore, THC, which acts
through activation of CB1 receptors, is known to increase
firing of dopaminergic neurons in the midbrain (Diana
et al, 1998; French et al, 1997) and these same midbrain
dopamine neurons regulate excitatory and inhibitory inputs
by retrograde endocannabinoid signaling (Chevaleyre et al,
2006; Lupica and Riegel, 2005; Matyas et al, 2008). The
effects of cannabinoids such as THC on dopaminergic
mesolimbic neurotransmission are usually indirect (Fernandez-
Ruiz et al, 2010); it is thought that CB1R at GABAergic and
NPG_NPP_NPP201224
Figure 3 Cannabinoid receptor 1 (CB1R) intensity in prefrontal cortex (PFC) (a) and hippocampus (HPC) (b), PV cell size in PFC (c) and HPC (d), and
PV cell density in PFC (e) and HPC (f) during adulthood, following adolescent treatment with 8.0mg/kg delta-9-tetrahydrocannabinol (THC) or vehicle (0).
Data are means±SEM; *po0.015.
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glutamatergic synapses facilitate such indirect actions
(Herkenham et al, 1990; Mailleux and Vanderhaeghen,
1992; Tsou et al, 1998). Therefore, our findings of smaller
VTA dopaminergic neurons following THC treatment may
occur in response to higher cortical CB1R levels in COMT
KO mice (Akil et al, 2003). Our finding that adolescent THC
treatment and COMT genotype interact to modulate VTA
dopaminergic neuron size in adult mice may reflect an
effect of endocannabinoid regulation on mesolimbic dopa-
minergic neuron populations following adolescent THC
exposure, a critical period of brain development (Ehren-
reich et al, 1999; Pope et al, 2003). On this basis, we propose
that dysregulation of dopaminergic neurons in VTA in
schizophrenia (Akil et al, 2003; Bilder et al, 2004) may be
exacerbated by adolescent THC-induced, CB1R-mediated,
long-term impairment in mesolimbic dopaminergic neuron
structure and, hence, signaling.
GABAergic neurons. Dysfunction in GABAergic systems
is evident in schizophrenia, with GABA synthesis and
reuptake reduced in PFC and HPC (Heckers et al, 2002;
Konradi et al, 2011; Volk et al, 2001). Furthermore, cell
density of GABAergic neurons, in particular the number of
PV-positive neurons, is decreased in PFC and HPC of patients
with schizophrenia (Benes et al, 1991, 1998; Hashimoto
et al, 2003; Konradi et al, 2011). Given these studies and
based on a higher COMT activity being a risk factor for
schizophrenia, one would have predicted deficits in cortical
GABAergic neuronal populations in COMT WT mice, where
the PFC would be hypodopaminergic and GABAergic
inhibition would not be strong. Instead, GABAergic deficits
were observed by a reduction in cell size in COMT KO mice
and not COMT WT mice. The conventional inverted-U
shape curve of dopaminergic modulation of the PFC activity
may provide some understanding given that deficient or
excessive dopamine activity exert disruptive effects on normal
neuronal structure (Seamans and Yang, 2004). As dopamine
is capable of having an inhibitory effect on cortical GABA
neurons (Retaux et al, 1991), it is possible that an excessive
release of prefrontal dopamine in COMT KO mice could
lead to impairments in normal GABAergic neuronal structure.
Conversely, GABAergic neurons in VTA are anatomically
positioned to influence the activity of the dopamine system
in the mesolimbic pathway (Laviolette and van der Kooy,
2001); so, changes in GABAergic neurons could be responsible
for altering the activity and structure of neighboring dopa-
minergic neurons.
It is not yet clear how reduction in the size of PV+
GABAergic neurons in COMT KO mice in response to
adolescent THC treatment relates to the upregulation of
cortical CB1R protein expression in COMT HET and KO
mice, following adolescent THC exposure. However, given
our findings of a significant inverse correlation between
CB1R and PV cell size and that endocannabinoids are
known to modify inhibition in GABAergic neurons (Lovinger,
2008), it is also possible that enhanced expression of cortical
CB1R (by THC treatment) may alter the size of cortical
GABAergic populations and, consequently, modify GA-
BAergic signaling in COMT mutant mice. Our GABAergic
findings in the COMT mutant mouse are interesting, given
that most of the effects of the endocannabinoid system on
dopaminergic neurotransmission are GABA- and/or gluta-
mate-mediated (Herkenham et al, 1990; Mailleux and
Vanderhaeghen, 1992; Tsou et al, 1998). Q3Additionally,
endocannabinoids such as THC are responsible for retrograde
signaling of CB1R on GABAergic neurons and, through this
mechanism, can prevent excess inhibition at GABAergic
synapses (Lovinger, 2008). Upregulation of cortical CB1R
protein expression in COMT HET and KO mice, following
adolescent THC exposure, may thus mediate the reduction
observed in midbrain dopaminergic neuronal cell size
through CB1Rs cortical action on GABAergic neurons. How
this occurs may have a functional origin arising from a
dampened inhibition of GABAergic neurons brought, which,
in turn, can be mediated by the increased expression observed
in CB1R-enhanced endocannabinoid signaling (Lovinger,
2008).
There is certainly a higher order of complexity in how
these systems interact that should be interpreted with
caution. Nonetheless, the GABAergic changes observed in
this gene environmental mouse model and their relation-
ship to schizophrenia indicate further the vulnerability to,
and consequent dysregulation of, neurotransmitter systems
by developmental insults such as THC treatment during
adolescence.
Summary
These studies elaborate and suggest putative mechanisms
underlying recent clinical findings that cannabis use during
adolescence, and subsequent psychosis is influenced by the
human COMT genotype (Caspi et al, 2005). The higher
activity COMT Val allele has demonstrated in some, but not
all, human studies to be associated with increased risk of
schizophrenia following THC exposure during adolescence
(Caspi et al, 2005; Zammit et al, 2011). It might have been
predicted, based on a higher COMT activity being a risk
factor for schizophrenia, that COMT KO mice exposed to
adolescent THC would evidence fewer schizophrenia-related
neuronal changes than WT mice, that is, relative hyperdo-
paminergia in mesolimbic systems (Akil et al, 2003), reduced
density of cortical and hippocampal GABAergic neurons
(Cotter et al, 2002a), and reduced CB1R expression (Eggan
et al, 2010). However, the opposite was observed; COMT KO
mice demonstrated the more prominent structural neuronal
deficits. These findings may reflect complexities arising
from the inverted U-shaped relationship between cortical-
mediated function and cortical dopaminergic activity in
human/non-human primates vis-a`-vis rodents, such that
deficient or excessive dopamine activity could each
exert disruptive effects on normal neuronal structure
(O’Tuathaigh et al, 2010, 2011; Seamans and Yang, 2004;
Tunbridge et al, 2006). Additionally, future comparative
studies investigating these same paradigms in mice expres-
sing variants of human COMT are required to rule out any
probability of our COMT KO findings arising from
developmental compensation in dopaminergic, CB1R, and
GABAergic systems.
Our findings indicate disruptive effects of adolescent THC
exposure on several neuronal populations, in a manner that
can be modulated by COMT genotype. They demonstrate
how genetic, developmental, and environmental factors
can interact to modulate the cellular structure of neuronal
NPG_NPP_NPP201224
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populations implicated in schizophrenia such as the dopa-
minergic, endocannabinoid, and GABAergic systems.
ACKNOWLEDGEMENTS
This study was supported by Science Foundation Ireland
(DC: 05/RFP/BMI0016; JLW: 07/IN.1/B960), and the Health
Research Board (CO’T: PD/2007/20; MC: CSA/2004/1).
DISCLOSURE
The authors declare no conflict of interest.
REFERENCES
Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR,
Kleinman JE (2003). Catechol-O-methyltransferase genotype and
dopamine regulation in the human brain. J Neurosci 23: 2008–
2013.
Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-
Saleh MT (2008). Corpus callosum damage in heavy marijuana
use: preliminary evidence from diffusion tensor tractography
and tract-based spatial statistics. Neuroimage 41: 1067–1074.
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE
(2002). Cannabis use in adolescence and risk for adult psychosis:
longitudinal prospective study. BMJ 325: 1212–1213.
Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal
association between cannabis and psychosis: examination of the
evidence. Br J Psychiatry 184: 110–117.
Babovic D, O’Tuathaigh CM, O’Sullivan GJ, Clifford JJ, Tighe O,
Croke DT et al (2007). Exploratory and habituation phenotype of
heterozygous and homozygous COMT knockout mice. Behav
Brain Res 183: 236–239.
Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR (2009).
Proteomic analysis of membrane microdomain-associated pro-
teins in the dorsolateral prefrontal cortex in schizophrenia and
bipolar disorder reveals alterations in LAMP, STXBP1 and
BASP1 protein expression. Mol Psychiatry 14: 601–613.
Behan AT, van den Hove DL, Mueller L, Jetten MJ, Steinbusch HW,
Cotter DR et al (2010). Evidence of female-specific glial deficits
in the hippocampus in a mouse model of prenatal stress. Eur
Neuropsychopharmacol 21: 71–79.
Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The
ontogeny of cannabinoid receptors in the brain of postnatal and
aging rats. Neurotoxicol Teratol 17: 25–30.
Benes FM, Kwok EW, Vincent SL, Todtenkopf MS (1998). A
reduction of nonpyramidal cells in sector CA2 of schizophrenics
and manic depressives. Biol Psychiatry 44: 88–97.
Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL
(1991). Deficits in small interneurons in prefrontal and cingulate
cortices of schizophrenic and schizoaffective patients. Arch Gen
Psychiatry 48: 996–1001.
Bilder RM, Volavka J, Lachman HM, Grace AA (2004). The
catechol-O-methyltransferase polymorphism: relations to the
tonic-phasic dopamine hypothesis and neuropsychiatric pheno-
types. Neuropsychopharmacology 29: 1943–1961.
Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC,
Windhorst AD et al (2009). Delta 9-tetrahydrocannabinol
induces dopamine release in the human striatum. Neuropsycho-
pharmacology 34: 759–766.
Carlsson A (1978). Does dopamine have a role in schizophrenia?
Biol Psychiatry 13: 3–21.
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H
et al (2005). Moderation of the effect of adolescent-onset
cannabis use on adult psychosis by a functional polymorphism
in the catechol-O-methyltransferase gene: longitudinal evidence
of a gene X environment interaction. Biol Psychiatry 57: 1117–
1127.
Castner SA, Williams GV, Goldman-Rakic PS (2000). Reversal of
antipsychotic-induced working memory deficits by short-term
dopamine D1 receptor stimulation. Science 287: 2020–2022.
Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM
(2004). Cannabinoids enhance subsecond dopamine release
in the nucleus accumbens of awake rats. J Neurosci 24:
4393–4400.
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al
(2004). Functional analysis of genetic variation in catechol-O-
methyltransferase (COMT): effects on mRNA, protein, and
enzyme activity in postmortem human brain. Am J Hum Genet
75: 807–821.
Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990).
Delta 9-tetrahydrocannabinol produces naloxone-blockable en-
hancement of presynaptic basal dopamine efflux in nucleus
accumbens of conscious, freely-moving rats as measured by
intracerebral microdialysis. Psychopharmacology (Berl) 102:
156–162.
Chevaleyre V, Takahashi KA, Castillo PE (2006). Endocannabi-
noid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci
29: 37–76.
Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L
et al (2002a). The density and spatial distribution of GABAergic
neurons, labelled using calcium binding proteins, in the anterior
cingulate cortex in major depressive disorder, bipolar disorder,
and schizophrenia. Biol Psychiatry 51: 377–386.
Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP
(2002b). Reduced neuronal size and glial cell density in area 9 of
the dorsolateral prefrontal cortex in subjects with major
depressive disorder. Cereb Cortex 12: 386–394.
Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in
schizophrenia: a review and reconceptualization. Am J Psychia-
try 148: 1474–1486.
Diana M, Melis M, Gessa GL (1998). Increase in meso-prefrontal
dopaminergic activity after stimulation of CB1 receptors by
cannabinoids. Eur J Neurosci 10: 2825–2830.
D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K,
Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol
effects in schizophrenia: implications for cognition, psychosis,
and addiction. Biol Psychiatry 57: 594–608.
Eggan SM, Stoyak SR, Verrico CD, Lewis DA (2010). Cannabinoid
CB1 receptor immunoreactivity in the prefrontal cortex:
comparison of schizophrenia and major depressive disorder.
Neuropsychopharmacology 35: 2060–2071.
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling
L et al (1999). Specific attentional dysfunction in adults
following early start of cannabis use. Psychopharmacology (Berl)
142: 295–301.
Fernandez-Ruiz J, Hernandez M, Ramos JA (2010). Cannabinoid-
dopamine interaction in the pathophysiology and treatment of
CNS disorders. CNS Neurosci Ther 16: e72–e91.
French ED (1997). delta9-Tetrahydrocannabinol excites rat VTA
dopamine neurons through activation of cannabinoid CB1 but
not opioid receptors. Neurosci Lett 226: 159–162.
French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine
neurons in the ventral tegmentum and substantia nigra.
Neuroreport 8: 649–652.
Freund TF, Katona I, Piomelli D (2003). Role of endogenous
cannabinoids in synaptic signaling. Physiol Rev 83: 1017–1066.
Fride E (2005). Endocannabinoids in the central nervous system:
from neuronal networks to behavior. Curr Drug Targets CNS
Neurol Disord 4: 633–642.
Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al
(1998). Catechol-O-methyltransferase-deficient mice exhibit sex-
ually dimorphic changes in catecholamine levels and behavior.
Proc Natl Acad Sci USA 95: 9991–9996.
NPG_NPP_NPP201224
Adolescent THC exposure in COMT knockout mice
A´T Behan et al
9
Neuropsychopharmacology
Goldman-Rakic PS, Muly 3rd EC, Williams GV (2000). D(1)
receptors in prefrontal cells and circuits. Brain Res Brain Res Rev
31: 295–301.
Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L,
Marcussen N et al (1988). The new stereological tools: disector,
fractionator, nucleator and point sampled intercepts and their
use in pathological research and diagnosis. APMIS 96: 857–881.
Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene
expression, and neuropathology: on the matter of their
convergence. Mol Psychiatry 10: 40–68.
Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z
et al (2003). Gene expression deficits in a subclass of GABA
neurons in the prefrontal cortex of subjects with schizophrenia.
J Neurosci 23: 6315–6326.
Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM (2002).
Differential hippocampal expression of glutamic acid decarbox-
ylase 65 and 67 messenger RNA in bipolar disorder and
schizophrenia. Arch Gen Psychiatry 59: 521–529.
Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen
HU et al (2005). Prospective cohort study of cannabis use,
predisposition for psychosis, and psychotic symptoms in young
people. BMJ 330: 11.
Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker
M et al (2006). An experimental study of catechol-o-methyltrans-
ferase Val158Met moderation of delta-9-tetrahydrocannabinol-
induced effects on psychosis and cognition.Neuropsychopharmacology
31: 2748–2757.
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS,
de Costa BR et al (1990). Cannabinoid receptor localization in
brain. Proc Natl Acad Sci USA 87: 1932–1936.
Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J
(2008). Early exposure to cannabis and risk for psychosis in
young adolescents in Trinidad. Acta Psychiatr Scand 118:
209–213.
Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P,
Pantazopoulos H et al (2011). Hippocampal interneurons are
abnormal in schizophrenia. Schizophr Res 131: 165–173.
Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL,
Weinshilboum RM (1996). Human catechol-O-methyltransferase
pharmacogenetics: description of a functional polymorphism
and its potential application to neuropsychiatric disorders.
Pharmacogenetics 6: 243–250.
Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P,
Manzoni OJ (2007). Molecular components and functions of
the endocannabinoid system in mouse prefrontal cortex. PLoS
One 2: e709.
Laviolette SR, Grace AA (2006). The roles of cannabinoid and
dopamine receptor systems in neural emotional learning
circuits: implications for schizophrenia and addiction. Cell Mol
Life Sci 63: 1597–1613.
Laviolette SR, van der Kooy D (2001). GABA(A) receptors in the
ventral tegmental area control bidirectional reward signalling
between dopaminergic and non-dopaminergic neural motiva-
tional systems. Eur J Neurosci 13: 1009–1015.
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S
et al (2008). Circuit-based framework for understanding
neurotransmitter and risk gene interactions in schizophrenia.
Trends Neurosci 31: 234–242.
Lovinger DM (2008). Presynaptic modulation by endocannabi-
noids. Handb Exp Pharmacol 184: 435–477.
Lupica CR, Riegel AC (2005). Endocannabinoid release from
midbrain dopamine neurons: a potential substrate for cannabi-
noid receptor antagonist treatment of addiction. Neuropharma-
cology 48: 1105–1116.
Mailleux P, Vanderhaeghen JJ (1992). Distribution of neuronal
cannabinoid receptor in the adult rat brain: a comparative
receptor binding radioautography and in situ hybridization
histochemistry. Neuroscience 48: 655–668.
Matochik JA, Eldreth DA, Cadet JL, Bolla KI (2005). Altered brain
tissue composition in heavy marijuana users. Drug Alcohol
Depend 77: 23–30.
Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund
TF et al (2008). Identification of the sites of 2-arachidonoylgly-
cerol synthesis and action imply retrograde endocannabinoid
signaling at both GABAergic and glutamatergic synapses in the
ventral tegmental area. Neuropharmacology 54: 95–107.
McGrath J, Welham J, Scott J, Varghese D, Degenhardt L,
Hayatbakhsh MR et al (2010). Association between cannabis
use and psychosis-related outcomes using sibling pair analysis in
a cohort of young adults. Arch Gen Psychiatry 67: 440–447.
McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley
DE et al (2008). Dose-related differences in the regional pattern
of cannabinoid receptor adaptation and in vivo tolerance
development to delta9-tetrahydrocannabinol. J Pharmacol Exp
Ther 324: 664–673.
McLaughlin CR, Martin BR, Compton DR, Abood ME (1994).
Cannabinoid receptors in developing rats: detection of mRNA
and receptor binding. Drug Alcohol Depend 36: 27–31.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB,
Burke M et al (2007). Cannabis use and risk of psychotic or
affective mental health outcomes: a systematic review. Lancet
370: 319–328.
O’Tuathaigh CM, Babovic D, O’Meara G, Clifford JJ, Croke DT,
Waddington JL (2007). Susceptibility genes for schizophrenia:
characterisation of mutant mouse models at the level of
phenotypic behaviour. Neurosci Biobehav Rev 31: 60–78.
O’Tuathaigh CM, Clarke G, Walsh J, Desbonnet L, Petit E,
O’Leary C et al (2011). Genetic vs pharmacological inactivation
of COMT influences cannabinoid-induced expression of schizo-
phrenia-related phenotypes Q4. Int J Neuropsychopharmacol: 1–12.
O’Tuathaigh CM, Hryniewiecka M, Behan A´, Tighe O, Coughlan C,
Desbonnet L et al (2010). Chronic adolescent exposure to delta-
9-tetrahydrocannabinol in COMT mutant mice: impact on
psychosis-related and other phenotypes. Neuropsychopharma-
cology 35: 2262–2273.
Paxinos F (2008). The Mouse Brain in Stereotaxic Coordinates,
Compact, Third Edition: The Coronal Plates and Diagrams, 3
edn. Academic Press: Allen Institute Q5.
Pertwee RG (2005). Pharmacological actions of cannabinoids.
Handb Exp Pharmacol 168: 1–51.
Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL et al
(2002). Delta(9)-tetrahydrocannabinol decreases extracellular
GABA and increases extracellular glutamate and dopamine
levels in the rat prefrontal cortex: an in vivo microdialysis study.
Brain Res 948: 155–158.
Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL
(2004). Adolescent exposure to cannabinoids induces long-
lasting changes in the response to drugs of abuse of rat midbrain
dopamine neurons. Biol Psychiatry 56: 86–94.
Pope Jr HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA,
Yurgelun-Todd D (2003). Early-onset cannabis use and cognitive
deficits: what is the nature of the association? Drug Alcohol
Depend 69: 303–310.
Retaux S, Besson MJ, Penit-Soria J (1991). Synergism between D1
and D2 dopamine receptors in the inhibition of the evoked
release of [3H]GABA in the rat prefrontal cortex. Neuroscience
43: 323–329.
Romero J, Berrendero F, Manzanares J, Perez A, Corchero J,
Fuentes JA et al (1998). Time-course of the cannabinoid receptor
down-regulation in the adult rat brain caused by repeated
exposure to delta9-tetrahydrocannabinol. Synapse 30: 298–308.
Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA,
Fernandez-Ruiz JJ (1997). Effects of chronic exposure to delta9-
tetrahydrocannabinol on cannabinoid receptor binding and
mRNA levels in several rat brain regions. Brain Res Mol Brain
Res 46: 100–108.
NPG_NPP_NPP201224
Adolescent THC exposure in COMT knockout mice
A´T Behan et al
10
Neuropsychopharmacology
Scatton B, Dubois A, Dubocovich ML, Zahniser NR, Fage D (1985).
Quantitative autoradiography of 3H-nomifensine binding sites
in rat brain. Life Sci 36: 815–822.
Schneider M, Koch M (2003). Chronic pubertal, but not adult
chronic cannabinoid treatment impairs sensorimotor gating,
recognition memory, and the performance in a progressive ratio
task in adult rats. Neuropsychopharmacology 28: 1760–1769.
Seamans JK, Yang CR (2004). The principal features and
mechanisms of dopamine modulation in the prefrontal cortex.
Prog Neurobiol 74: 1–58.
Seeman P (1999). Images in neuroscience. Brain development, X:
pruning during development. Am J Psychiatry 156: 168.
Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van
Os J (2004). Early adolescent cannabis exposure and positive and
negative dimensions of psychosis. Addiction 99: 1333–1341.
Stokes PR, Egerton A, Watson B, Reid A, Breen G, Lingford-
Hughes A et al (2010). Significant decreases in frontal and
temporal [11C]-raclopride binding after THC challenge. Neuro-
image 52: 1521–1527.
Stokes PR, Egerton A, Watson B, Reid A, Lappin J, Howes OD et al
(2011). History of cannabis use is not associated with alterations
in striatal dopamine D2/D3 receptor availability. J Psychophar-
macol 26: 144–149.
Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin
activation of mesolimbic dopamine transmission by a common
mu1 opioid receptor mechanism. Science 276: 2048–2050.
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998).
Immunohistochemical distribution of cannabinoid CB1 recep-
tors in the rat central nervous system. Neuroscience 83: 393–411.
Tunbridge EM, Harrison PJ, Weinberger DR (2006). Catechol-o-
methyltransferase, cognition, and psychosis: Val158Met and
beyond. Biol Psychiatry 60: 141–151.
van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H
(2002). Cannabis use and psychosis: a longitudinal population-
based study. Am J Epidemiol 156: 319–327.
van Os J, Kenis G, Rutten BP (2010). The environment and
schizophrenia. Nature 468: 203–212.
Vazdarjanova A, Bunting K, Muthusamy N, Bergson C (2011).
Calcyon upregulation in adolescence impairs response inhibition
and working memory in adulthood. Mol Psychiatry 16: 672–684.
Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J (2003).
Cannabis use and dimensions of psychosis in a nonclinical
population of female subjects. Schizophr Res 59: 77–84.
Volk D, Austin M, Pierri J, Sampson A, Lewis D (2001). GABA
transporter-1 mRNA in the prefrontal cortex in schizophrenia:
decreased expression in a subset of neurons. Am J Psychiatry
158: 256–265.
Welch KA, McIntosh AM, Job DE, Whalley HC, Moorhead TW,
Hall J et al (2010). The impact of substance use on brain
structure in people at high risk of developing schizophrenia.
Schizophr Bull Q6.
Wilson N, Cadet JL (2009). Comorbid mood, psychosis, and
marijuana abuse disorders: a theoretical review. J Addict Dis 28:
309–319.
Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Mannisto PT
(2007). Site-specific role of catechol-O-methyltransferase in
dopamine overflow within prefrontal cortex and dorsal striatum.
J Neurosci 27: 10196–10209.
Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C
et al (2008). Regional brain abnormalities associated with
long-term heavy cannabis use. Arch Gen Psychiatry 65:
694–701.
Zammit S, Owen MJ, Evans J, Heron J, Lewis G (2011). Cannabis,
COMT and psychotic experiences. Br J Psychiatry 199: 380–385.
NPG_NPP_NPP201224
Adolescent THC exposure in COMT knockout mice
A´T Behan et al
11
Neuropsychopharmacology
